haematology
Multiple Myeloma Response Criteria (IMWG 2016)
International Myeloma Working Group (IMWG) 2016 response criteria for multiple myeloma. Used to assess depth of response to therapy. Guides treatment decisions: continuation, maintenance, or intensification. Includes stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD), and progressive disease (PD).
References
- Kumar S et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
- NICE TA587. Lenalidomide for maintenance treatment of multiple myeloma following an autologous stem cell transplant. NICE. 2019.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Dairy products · Nutritional source (calcium, protein, vitamin D)
- Bortezomib · Proteasome Inhibitor — Myeloma
- Thalidomide · Immunomodulatory Drug (IMiD) — Myeloma
- Daratumumab · Anti-CD38 Monoclonal Antibody — Myeloma
- Protein C (Specialist drug) · Recombinant/plasma-derived protein C concentrate
- Respiratory syncytial virus (RSV) vaccine · RSV pre-fusion F protein vaccine
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.